<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Alendronate and cholecalciferol: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Alendronate and cholecalciferol: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Alendronate and cholecalciferol: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11604" href="/d/html/11604.html" rel="external">see "Alendronate and cholecalciferol: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F596002"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Fosamax Plus D</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868673"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Alendronate/Vitamin D3;</li>
<li>Fosavance;</li>
<li>JAMP-Alendronate/Vit D3;</li>
<li>JAMP-Alendronate/Vitamin D3;</li>
<li>SANDOZ Alendronate/Cholecalcif [DSC];</li>
<li>TEVA-Alendronate/Cholecal [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F595968"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Bisphosphonate Derivative;</li>
<li>
                        Vitamin D Analog</li></ul></div>
<div class="block doa drugH1Div" id="F595992"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Avoid use in patients with swallowing difficulties, esophageal motility disorders, or the inability to stand or sit upright for ≥30 minutes. In patients treated for osteoporosis, correct hypocalcemia and vitamin D deficiency (eg, to a 25-hydroxyvitamin D level ≥20 ng/mL [≥50 nmol/L]) prior to initiating therapy and ensure adequate calcium intake during therapy; some patients may require additional vitamin D while taking this product (not intended to treat vitamin D deficiency) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30907953','lexi-content-ref-34448749','lexi-content-ref-Rosen.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30907953','lexi-content-ref-34448749','lexi-content-ref-Rosen.1','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="42d9f687-8a9c-4d6e-86a3-00829eb78170">Osteoporosis, fracture risk reduction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteoporosis, fracture risk reduction (males and postmenopausal females): Note:</b> Prior to use, evaluate and treat any potential causes of secondary osteoporosis (eg, severe vitamin D deficiency) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25182228']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25182228'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients with high fracture risk, including those with a history of fragility fracture, <b>or</b> males ≥50 years of age and postmenopausal females with a T-score of −2.5 or lower or a T-score between −1 and −2.5 at high fracture risk according to a risk assessment</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Finkelstein.1','lexi-content-ref-25182228']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Finkelstein.1','lexi-content-ref-25182228'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Treatment:</b>
<b>Oral:</b> One tablet (alendronate 70 mg/cholecalciferol 2,800 units <b>or</b> alendronate 70 mg/cholecalciferol 5,600 units) once weekly.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Duration of therapy:</b> The optimal duration of therapy has not been established. Consider discontinuing after 5 years if bone mineral density (BMD) is stable, there have been no previous fragility fractures, and short-term fracture risk is low. If fracture risk remains high (eg, fragility fracture before or during therapy), consider extending therapy for up to 10 years or switching to alternative therapy. If discontinued, the decision to resume therapy is based on multiple factors, including decline in BMD and risk factors for fracture (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26350171','lexi-content-ref-30907953','lexi-content-ref-20173017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26350171','lexi-content-ref-30907953','lexi-content-ref-20173017'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed doses:</i> If a once-weekly dose is missed, administer the next morning after remembered. Then return to the original scheduled day of the week on the once-weekly schedule; however, do not administer 2 doses on the same day.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991154"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">CrCl ≥35 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">Cl<sub>cr </sub>&lt;35 mL/minute: Use is not recommended.</p></div>
<div class="block doha drugH1Div" id="F50988510"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Alendronate: No dosage adjustment necessary. Cholecalciferol: May not be adequately absorbed in patients who have malabsorption due to inadequate bile production.</p></div>
<div class="block doe drugH1Div" id="F2508494"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F595978"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">See individual agents.</p></div>
<div class="block coi drugH1Div" id="F595973"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to alendronate, vitamin D derivatives, or any component of the formulation; hypocalcemia; abnormalities of the esophagus (eg, stricture or achalasia) which delay esophageal emptying; inability to stand or sit upright for at least 30 minutes </p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Renal insufficiency with CrCl &lt;35 mL/minute</p></div>
<div class="block war drugH1Div" id="F595974"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone fractures: Atypical femur fractures (AFF) have been reported in patients receiving bisphosphonates. The fractures include subtrochanteric femur (bone just below the hip joint) and diaphyseal femur (long segment of the thigh bone). Some patients experience prodromal pain weeks or months before the fracture occurs. It is unclear if bisphosphonate therapy is the cause for these fractures; AFFs have also been reported in patients not taking bisphosphonates, and in patients receiving glucocorticoids. Patients receiving long-term (&gt;3 to 5 years) bisphosphonate therapy may be at an increased risk (Adler 2016; NOF [Cosman 2014]); however, benefits of therapy (when used for osteoporosis) generally outweigh absolute risk of AFF within the first 5 years of treatment, especially in patients with high fracture risk (Adler 2016; ES [Eastell 2019]). Patients presenting with thigh or groin pain with a history of receiving bisphosphonates should be evaluated for femur fracture. Consider interrupting bisphosphonate therapy in patients who develop a femoral shaft fracture; assess for fracture in the contralateral limb.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bone/joint/muscle pain: Severe (and occasionally debilitating) bone, joint, and/or muscle pain have been reported during bisphosphonate treatment. The onset of pain ranged from a single day to several months. Consider discontinuing therapy in patients who experience severe symptoms; symptoms usually resolve upon discontinuation. Some patients experienced recurrence when rechallenged with the same drug or another bisphosphonate; avoid use in patients with a history of these symptoms in association with bisphosphonate therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI mucosa irritation: May cause irritation to upper GI mucosa. Esophagitis, dysphagia, esophageal ulcers, esophageal erosions, and esophageal stricture (rare) have been reported with oral bisphosphonates; risk increases in patients unable to comply with dosing instructions. Use with caution in patients with dysphagia, esophageal disease, gastritis, duodenitis, or ulcers (may worsen underlying condition). Discontinue use if new or worsening symptoms develop.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular effects: Conjunctivitis, uveitis, episcleritis, and scleritis have been reported with alendronate; patients presenting with signs of ocular inflammation may require further ophthalmologic evaluation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Osteonecrosis of the jaw: Osteonecrosis of the jaw (ONJ), also referred to as medication-related osteonecrosis of the jaw (MRONJ), has been reported in patients receiving bisphosphonates. Known risk factors for MRONJ include invasive dental procedures (eg, tooth extraction, dental implants, boney surgery), cancer diagnosis, concomitant therapy (eg, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, ill-fitting dentures, and comorbid disorders (anemia, coagulopathy, infection, preexisting dental or periodontal disease). Risk may increase with increased duration of bisphosphonate use. According to a position paper by the American Association of Maxillofacial Surgeons (AAOMS), MRONJ has been associated with bisphosphonates and other antiresorptive agents (denosumab), and antiangiogenic agents (eg, bevacizumab, sunitinib) used for the treatment of osteoporosis or malignancy; risk of MRONJ is significantly higher in cancer patients receiving antiresorptive therapy compared to patients receiving osteoporosis treatment (regardless of medication used or dosing schedule). MRONJ risk is also increased with intravenous antiresorptive use compared with the minimal risk associated with oral bisphosphonate use, although risk appears to increase with oral bisphosphonates when duration of therapy exceeds 4 years (AAOMS [Ruggiero 2014]). The manufacturer’s labeling states that in patients requiring invasive dental procedures, discontinuing bisphosphonates may reduce the risk of ONJ, and clinical judgment should guide the decision. However, the AAOMS suggests there is currently no evidence that interrupting oral bisphosphonate therapy alters the risk of ONJ following tooth extraction, and that in patients receiving oral bisphosphonates for &lt;4 years who have no clinical risk factors, no alternations or delay in any procedure common to oral/maxillofacial surgeons, periodontists, and other dental providers is necessary (special considerations apply to patients receiving dental implants). Conversely, in patients receiving oral bisphosphonates for &gt;4 years or in patients receiving oral bisphosphonates for &lt;4 years who have also taken corticosteroids or antiangiogenic medications concomitantly, the AAOMS recommends considering a 2-month, drug-free period prior to invasive dental procedures (recommendation based on a theoretical benefit). Patients developing ONJ during therapy should receive care by an oral surgeon (AAOMS [Ruggiero 2014]). According to the manufacturer, discontinuation of the bisphosphonate therapy should be considered (based on risk/benefit evaluation) in patients who develop ONJ.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bariatric surgery: Altered absorption and ulceration risk: Avoid oral bisphosphates after bariatric surgery; inadequate oral absorption and potential anastomotic ulceration may occur. If therapy is indicated, IV administered bisphosphonates are recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI malabsorption syndrome: Increased doses of vitamin D supplementation may be required in patients with GI malabsorption syndrome; consider monitoring 25-hydroxy vitamin D levels.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypercalcemia: May exacerbate hypercalcemia and/or hypercalciuria in certain disease states (eg, leukemia, lymphoma, sarcoidosis); monitor serum and urine calcium levels.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypocalcemia/vitamin D deficiency: Before therapy initiation hypocalcemia and/or vitamin D deficiency must be corrected; ensure adequate calcium and vitamin D intake. Do not use to treat vitamin D deficiency.</p>
<p style="text-indent:-2em;margin-left:4em;">• Osteoporosis in survivors of adult cancers (nonmetastatic disease): Survivors of adult cancers with nonmetastatic disease who have osteoporosis (T score of -2.5 or lower in femoral neck, total hip or lumbar spine) or who are at increased risk of osteoporotic fractures, should be offered bone modifying agents (utilizing the osteoporosis-indicated dose) to reduce the risk of fracture. For patients without hormonal responsive cancers, when clinically appropriate, estrogens may be administered along with other bone modifying agents (ASCO [Shapiro 2019]). The choice of bone modifying agent (eg, oral or IV bisphosphonates or subcutaneous denosumab) should be based on several factors (eg, patient preference, potential adverse effects, quality of life considerations, availability, adherence, cost). Adequate calcium and vitamin D intake, exercise (using a combination of exercise types), as well as lifestyle modifications (if indicated) should also be encouraged.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment (not recommended for use in patients with CrCl &lt;35 mL/minute).</p></div>
<div class="block foc drugH1Div" id="F595999"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fosamax Plus D: Alendronate sodium 70 mg and cholecalciferol 2,800 units, Alendronate sodium 70 mg and cholecalciferol 5,600 units</p></div>
<div class="block geq drugH1Div" id="F595966"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F3422178"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Fosamax Plus D Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">70-2800 mg-unit (per each): $59.78</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">70-5600 mg-unit (per each): $59.78</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868674"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fosavance: Alendronate sodium 70 mg and cholecalciferol 2,800 units, Alendronate sodium 70 mg and cholecalciferol 5,600 units [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Alendronate sodium 70 mg and cholecalciferol 2,800 units, Alendronate sodium 70 mg and cholecalciferol 5,600 units</p></div>
<div class="block adm drugH1Div" id="F595995"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Administer first thing in the morning and ≥30 minutes before the first food, beverage (except plain water), or other medication(s) of the day. Must be taken with 6 to 8 oz of plain water; do not take with mineral water or with other beverages. Swallow whole; do not chew or suck. Patients should be instructed to stay upright (not to lie down) for ≥30 minutes <b>and</b> until after first food of the day (to reduce esophageal irritation).</p></div>
<div class="block meg drugH1Div" id="F11441251"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=http%3A%2F%2Fwww.fda.gov%2Fdownloads%2FDrugs%2FDrugSafety%2FUCM241521.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn%2F%2BBtau8Jzc5BLV85NUiGV68PWQUo7mtX1IWEvCmO5DW1g%3D%3D&amp;TOPIC_ID=8975" target="_blank">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM241521.pdf</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F595969"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteoporosis, fracture risk reduction: </b>Treatment of osteoporosis in postmenopausal females; treatment to increase bone mass in males with osteoporosis.</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: Not for use in the treatment of vitamin D deficiency.</p></div>
<div class="block mst drugH1Div" id="F7254243"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Fosamax Plus D may be confused with Fosamax</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298702"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F595984"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: May enhance the hypocalcemic effect of Bisphosphonate Derivatives. Aminoglycosides may enhance the nephrotoxic effect of Bisphosphonate Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiogenesis Inhibitors (Systemic): May enhance the adverse/toxic effect of Bisphosphonate Derivatives. Specifically, the risk for osteonecrosis of the jaw may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aspirin: May enhance the adverse/toxic effect of Alendronate. Specifically, the incidence of upper gastrointestinal adverse events may be increased<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bile Acid Sequestrants: May decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Management: Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (eg, cholestyramine). Separate administration of these agents by several hours to minimize the potential risk of interaction. Monitor plasma calcium concentrations.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Salts: May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cardiac Glycosides: Vitamin D Analogs may enhance the arrhythmogenic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Danazol: May enhance the hypercalcemic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferasirox: Bisphosphonate Derivatives may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: Serum Phosphate Level-Altering Agents may diminish the therapeutic effect of Erdafitinib.  Management: Avoid coadministration of serum phosphate level-altering agents with erdafitinib before initial dose increase period based on serum phosphate levels (Days 14 to 21).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhibitors of the Proton Pump (PPIs and PCABs): May diminish the therapeutic effect of Bisphosphonate Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mineral Oil: May decrease the serum concentration of Vitamin D Analogs. More specifically, mineral oil may interfere with the absorption of Vitamin D Analogs. Management: Avoid concomitant, oral administration of mineral oil and vitamin D analogs. Consider separating the administration of these agents by several hours to minimize the risk of interaction. Monitor plasma calcium concentrations.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orlistat: May decrease the absorption of Vitamins (Fat Soluble). Management: Administer oral fat soluble vitamins at least 2 hours before or 2 hours after the administration of orlistat. Avoid concomitant administration due to the risk of impaired vitamin absorption.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Parathyroid Hormone: Alendronate may diminish the therapeutic effect of Parathyroid Hormone. More specifically, Alendronate may interfere with normalization of blood calcium concentrations. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyvalent Cation Containing Products: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral medications containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May enhance the hypercalcemic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin D Analogs: May enhance the adverse/toxic effect of other Vitamin D Analogs.<i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F595985"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">See individual agents.</p></div>
<div class="block pri drugH1Div" id="F595971"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Refer to individual monographs.</p></div>
<div class="block brc drugH1Div" id="F20471717"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Cholecalciferol is present in breast milk; it is not known if alendronate is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, benefits of breastfeeding to the infant, and benefits of treatment to the mother. Refer to individual monographs for additional information.</p></div>
<div class="block dic drugH1Div" id="F595994"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Ensure adequate calcium and vitamin D intake; if dietary intake is inadequate, dietary supplementation is recommended. Patients should consume:</p>
<p style="text-indent:-2em;margin-left:4em;">Calcium (elemental): 1,000 mg/day (males: 50 to 70 years of age) <b>or</b> 1,200 mg/day (females ≥51 years of age and males ≥71 years of age) (IOM 2011; NOF [Cosman 2014]).</p>
<p style="text-indent:-2em;margin-left:4em;">Vitamin D: 20 to 25 mcg/day (800 to 1,000 units/day) (≥50 years of age) (NOF [Cosman 2014]). Recommended dietary allowance: 15 mcg/day (600 units/day) (≤70 years of age) <b>or</b> 20 mcg/day (800 units/day) (≥71 years of age) (IOM 2011).</p></div>
<div class="block mop drugH1Div" id="F595997"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Serial bone mineral density (BMD) should be evaluated at baseline and every 1 to 3 years on treatment (usually at ~2 years following initiation of therapy, then more or less frequently depending on patient-specific factors and stability of BMD) (AACE/ACE [Camacho 2020]; ES [Eastell 2019]; NOF [Cosman 2014]); evaluate BMD every 2 to 4 years during a drug holiday (ES [Eastell 2019]); annual measurements of height and weight, assessment of chronic back pain; serum calcium and 25(OH)D; may consider monitoring biochemical markers of bone turnover (eg, fasting serum CTX or urinary NTX) at baseline, 3 months, and 6 months, to assess treatment response, adherence to therapy, and/or possible malabsorption (ES [Eastell 2019]).</p></div>
<div class="block rer drugH1Div" id="F595990"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Vitamin D: Patients with osteoporosis: Recommended level to reach and maintain may vary by guideline/organization: ≥20 ng/mL (50 nmol/L) is considered adequate according to some experts (ES [Eastell 2019]); others suggest a goal of ~30 ng/mL (75 nmol/L) (NOF [Cosman 2014]). There are insufficient data to determine the safe upper limit of serum 25(OH)D. Serum 25(OH)D levels above approximately 50 ng/mL (125 nmol/L) should be avoided (IOM 2011).</p></div>
<div class="block pha drugH1Div" id="F595988"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">See individual agents.</p></div>
<div class="block phk drugH1Div" id="F10143545"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">See individual agents.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F4301378"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Bonyl plus</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Fosamax Plus | Marvil D</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Alendrobell plus d3 | Alendronate D3 | Alendronate plus d3 | APO Alendronate Plus D3 | Dronalen Plus | Fonat plus | Fosamax Plus</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Alen d | Bonemass D</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Alendronate vitamine d3 teva | Fosavance</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Fosavance</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Fosamax D</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Alendron d3 mepha | Fosavance</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Fosamax Plus</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">A lun lin suan na wei D3 pian | Alendronate sodium and vitamin d3</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Alendronato sodico+ vitamina d | Osficar Plus</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Alendronic acid/vitamin D3 accord | Alendronic acid/vitamin d3 aurovitas | Alendronic acid/vitamin d3 mylan | Fosavance</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Alendron 1 A Pharma plus D | Alendron hexal plus d | Alendronsaeure Colecalciferol Aristo | Alendronsaeure heumann plus colecalciferol | Alendronsaeure/Colecalciferol AbZ | Fosavance</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Fosamax Plus | Marvil D | Oseomax D | Ostefort plus | Porosin D</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Osteoplus d | Osteoplus Duo</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Alendronic acid/colecalciferol sandoz</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Basebone | Blastoclast | Debosteobone | Delendrozen | Egydronate | Fosavance | Rotalbone D</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Acido alendronico Colecalciferol ratiopharm | Acido alendronico Colecalciferol semanal sandoz | Acido alendronico Colecalciferol tevagen | Acido alendronico/colecalciferol qualigen | Acido alendronico/colecalciferol semanal aristo | Acido alendronico/colecalciferol semanal aurovitas | Acido alendronico/colecalciferol semanal kern | Adrovance | Fosavance</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Fosastad | Fosavance</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Acide alendronique/cholecalciferol (vitamine d3) zentiva | Acide alendronique/vitamine d3 arrow | Acide alendronique/vitamine d3 bgr | Acide alendronique/vitamine d3 Mylan | Alendronate vitamine d3 teva | Fosavance</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Alendronic Acid/Colecalciferol | Bentexo</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Coved | Difocidol</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Fosamax Plus</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Fosavance</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Fosamax Plus</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Alendronate/colecalciferol rowex | Alendronic acid/cholecalciferol accord | Fosavance</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Aldotas d | Alenost d | Alensol d | Fosavance | Goldcal alen</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Adrovance | Alendronato e colecalciferolo accord | Alendronato e colecalciferolo aristo | Alendronato e Colecalciferolo Mylan Pharma | Alendronato e colecalciferolo teva | Fosavance | Vantavo</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Fosavance</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Aidbone plus d | Aldmac plus d | Alen plus d | Alend bone plus d | Alend plus d | Alendros plus d | Alenfos plus d | AlenHu Plus D | Alenmax plus d | Alent plus d | Aletron D | Allentop plus d | Allobone plus d | Alonate plus | Bonamax plus d | Boneaid plus d | Bonomax plus d | Bonpil plus d | Daewoong alendronate d | Densibone plus d | Forend plus d | Fosadronplus d | Fosajenic Plus D | Fosalong plusD | Fosamax Plus | Fosamax plus d | Gynodron plus d | J ferol | Marvil w plus | Os Plus D | Plus d aledron | Posarend plus d</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Fosavance</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Fosavance</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Fosavance</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Alendronic Acid/Colecalciferol | Alendronic acid/colecalciferol zentiva | Fosavance</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Fosavance</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Apodrolen d | Bonferol | Cuyulid | Fosamax Plus</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Adrovance | Alendroninezuur/cholecalciferol aurobindo | Alendroninezuur/Cholecalciferol sandoz | Fosavance | Vantavo</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Fosavance</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Fosamax Plus | Leodrin 70 Plus</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Bomax + D | Resovon</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Alendix | Alendroflex D | Alendrogen plus | Caldron | Ciferol | Drate Plus D | Fosnate d | Fosval d | Lendrol D | Nate d | Ostemet | Pronat D | Safbon d</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Fosamax plus d</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Acido alendronico + colecalciferol aristo | Acido alendronico + Colecalciferol Azevedos | Acido alendronico + Colecalciferol Bluepharma | Acido alendronico + colecalciferol ciclum | Acido Alendronico + Colecalciferol Generis | Acido alendronico + Colecalciferol Mylan | Acido alendronico + Colecalciferol Pharmakern | Acido alendronico + colecalciferol ratiopharm | Acido Alendronico + Colecalciferol Sandoz | Acido Alendronico + Colecalciferol toLife | Acido alendronico + Colecalciferol zentiva | Fosavance</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Fosavance</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Acid alendronic / colecalciferol sandoz | Acid alendronic/colecalciferol accord | Acid alendronic/colecalciferol aurobindo | Acid alendronic/colecalciferol zentiva | Da bone | Fosavance</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Fosavance</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Alendronate/cholecalciferol accord | Fosastad | Fosavance</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Fosamax Plus</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Fosalen d3</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Rebone | Vegabon plus D</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Fosamax Plus | PlusDmax</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Alendron d3 vista</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Marvil D</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Fosamax Plus</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Agostini | Alendro d | Ostagi d3 plus</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Fosavance</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-26350171">
<a name="26350171"></a>Adler RA, El-Hajj Fuleihan G, Bauer DC, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a Task Force of the American Society for Bone and Mineral Research [published correction appears in <i>J Bone Miner Res</i>. 2016;31(10):1910]. <i>J Bone Miner Res</i>. 2016;31(1):16-35. doi: 10.1002/jbmr.2708.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-and-cholecalciferol-drug-information/abstract-text/26350171/pubmed" id="26350171" target="_blank">26350171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30518604">
<a name="30518604"></a>Bartel TB, Kuruva M, Gnanasegaran G, et al. SNMMI procedure standard for bone scintigraphy 4.0. <i>J Nucl Med Technol</i>. 2018;46(4):398-404.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-and-cholecalciferol-drug-information/abstract-text/30518604/pubmed" id="30518604" target="_blank">30518604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32427503">
<a name="32427503"></a>Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. <i>Endocr Pract</i>. 2020;26(suppl 1):s1-s46. doi:10.4158/GL-2020-0524SUPPL<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-and-cholecalciferol-drug-information/abstract-text/32427503/pubmed" id="32427503" target="_blank">32427503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25182228">
<a name="25182228"></a>Cosman F, de Beur SJ, LeBoff MS, et al; National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis [published correction appears in <i>Osteoporos Int</i>. 2015;26(7):2045-2047]. <i>Osteoporos Int</i>. 2014;25(10):2359-2381. doi:10.1007/s00198-014-2794-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-and-cholecalciferol-drug-information/abstract-text/25182228/pubmed" id="25182228" target="_blank">25182228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30907953">
<a name="30907953"></a>Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2019;104(5):1595-1622. doi: 10.1210/jc.2019-00221.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-and-cholecalciferol-drug-information/abstract-text/30907953/pubmed" id="30907953" target="_blank">30907953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Finkelstein.1">
<a name="Finkelstein.1"></a>Finkelstein JS. Treatment of osteoporosis in men. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed February 14, 2022.</div>
</li>
<li>
<div class="reference">
                  Fosamax Plus D (alendronate/cholecalciferol) [prescribing information]. Jersey City, NJ: Organon LLC; August 2021.</div>
</li>
<li>
<div class="reference">
                  Fosavance (alendronate/cholecalciferol) [product monograph]. Kirkland, Quebec, Canada: Organon Canada Inc; May 2021.</div>
</li>
<li>
<div class="reference">
                  IOM (Institute of Medicine), <i>Dietary Reference Intakes for Calcium and Vitamin D,</i> Washington, DC: The National Academies Press, 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20061894">
<a name="20061894"></a>“Management of Osteoporosis in Postmenopausal Women: 2010 Position Statement of The North American Menopause Society,” <i>Menopause</i>, 2010, 17(1):25-54.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-and-cholecalciferol-drug-information/abstract-text/20061894/pubmed" id="20061894" target="_blank">20061894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34448749">
<a name="34448749"></a>North American Menopause Society (NAMS). Management of osteoporosis in postmenopausal women: the 2021 position statement of the North American Menopause Society. <i>Menopause</i>. 2021;28(9):973-997. doi:10.1097/GME.0000000000001831<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-and-cholecalciferol-drug-information/abstract-text/34448749/pubmed" id="34448749" target="_blank">34448749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rosen.1">
<a name="Rosen.1"></a>Rosen HN. Bisphosphonate therapy for the treatment of osteoporosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed February 14, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25234529">
<a name="25234529"></a>Ruggiero SL, Dodson TB, Fantasia J, et al; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. <i>J Oral Maxillofac Surg</i>. 2014;72(10):1938-1956. doi: 10.1016/j.joms.2014.04.031.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-and-cholecalciferol-drug-information/abstract-text/25234529/pubmed" id="25234529" target="_blank">25234529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20924014">
<a name="20924014"></a>Sellmeyer DE, “Atypical Fractures as a Potential Complication of Long-term Bisphosphonate Therapy,” <i>JAMA</i>, 2010, 304(13):1480-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-and-cholecalciferol-drug-information/abstract-text/20924014/pubmed" id="20924014" target="_blank">20924014</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20842676">
<a name="20842676"></a>Shane E, Burr D, Ebeling PR, et al, “Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Report of a Task Force of the American Society for Bone and Mineral Research,” <i>J Bone Miner Res</i>, 2010, 25(11):2267-94.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-and-cholecalciferol-drug-information/abstract-text/20842676/pubmed" id="20842676" target="_blank">20842676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31532726">
<a name="31532726"></a>Shapiro CL, Van Poznak C, Lacchetti C, et al. Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline. <i>J Clin Oncol</i>. 2019;37(31):2916-2946. doi: 10.1200/JCO.19.01696.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-and-cholecalciferol-drug-information/abstract-text/31532726/pubmed" id="31532726" target="_blank">31532726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24577348">
<a name="24577348"></a>Siris ES, Adler R, Bilezikian J, et al. The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. <i>Osteoporos Int</i>. 2014;25(5):1439-1443. doi: 10.1007/s00198-014-2655-z.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-and-cholecalciferol-drug-information/abstract-text/24577348/pubmed" id="24577348" target="_blank">24577348</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22675062">
<a name="22675062"></a>Watts NB, Adler RA, Bilezikian JP, et al; Endocrine Society. Osteoporosis in men: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2012;97(6):1802-1822. doi: 10.1210/jc.2011-3045.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-and-cholecalciferol-drug-information/abstract-text/22675062/pubmed" id="22675062" target="_blank">22675062</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20173017">
<a name="20173017"></a>Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. <i>J Clin Endocrinol Metab</i>. 2010;95(4):1555-1565. doi: 10.1210/jc.2009-1947.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-and-cholecalciferol-drug-information/abstract-text/20173017/pubmed" id="20173017" target="_blank">20173017</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8975 Version 209.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
